Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692597 · ClinicalTrials.gov registry record · NA
Low Level Laser Therapy (LLLT) for the Treatment of Hand Osteoarthritis.
A NA study, sponsored by David Moss.
- Terminated
- Registry status
- NA
- Development phase
- 83
- Enrollment target
NCT04692597: Clinical Trial NA study, sponsored by David Moss.
NCT04692597 is a NA study that was terminated before completion, run by David Moss. The registered enrollment target is 83 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04692597, a NA study, was terminated before completion, sponsored by David Moss.
- TERMINATED
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
Study Summary
This study is a randomized, control trial of Active Duty and DoD Beneficiaries, age 18 years or older, with complaints of hand osteoarthritis. Subjects will be randomized into one of two groups receiving either LLLT or sham LLLT. Subjects will receive LLLT or sham LLLT weekly over a period of six weeks. At each visit, patients will rate their pain using the Defense and Veterans Pain Rating Scale (DVPRS) and assess their functionality using the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire. Subjects will have a follow up visit six weeks after the treatment protocol for a final assessment of pain and function. The Phoenix Thera-Lase laser is a Class II, 510k cleared device (#K151521) and is legally marketed in the US. Investigators are using in accordance with its approved labeling and no changes to the approved labeling are being sought.
Primary Outcome
The DVPRS consists of an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain, and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS has demonstrated linear scale qualities allowing parametric methods to be used
Interventions
- DEVICE Phoenix Thera-Lase System
- DEVICE SHAM Phoenix Thera-Lase System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2025-12-09 |
| Phase | NA |
Why NCT04692597 stopped before completion
NCT04692597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Phoenix Thera-Lase System is the first listed.
NCT04692597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04692597 about?
NCT04692597 is a clinical study titled "Low Level Laser Therapy (LLLT) for the Treatment of Hand Osteoarthritis.". This study is a randomized, control trial of Active Duty and DoD Beneficiaries, age 18 years or older, with complaints of hand osteoarthritis. Subjects will be randomized into one of two groups receiving either LLLT or sham LLLT. Subjects will receive LLLT or sham LLLT weekly over a period of six we...
What is the current status of trial NCT04692597?
This trial is currently terminated. It is a NA study. The enrollment target is 83 participants. The study started on 2021-03-02. Estimated completion is 2025-12-09.
What interventions are being tested in trial NCT04692597?
The interventions under investigation include: Phoenix Thera-Lase System (DEVICE), SHAM Phoenix Thera-Lase System (DEVICE).
Who is sponsoring clinical trial NCT04692597?
This trial is sponsored by David Moss, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04692597's enrollment target sits among peer trials
83 990th of 2000 higher than 1,011 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI